Compare · NVO vs PYPD
NVO vs PYPD
Side-by-side comparison of Novo Nordisk A/S (NVO) and PolyPid Ltd. (PYPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PYPD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.28B, about 2250.7x PYPD ($87.2M).
- Over the past year, NVO is down 45.8% and PYPD is up 34.0% - PYPD leads by 79.8 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for PYPD).
- NVO has more recent analyst coverage (25 ratings vs 6 for PYPD).
- Company
- Novo Nordisk A/S
- PolyPid Ltd.
- Price
- $43.97+2.76%
- $4.57+0.66%
- Market cap
- $196.28B
- $87.2M
- 1M return
- -6.43%
- +1.44%
- 1Y return
- -45.76%
- +34.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest PYPD
- SEC Form 6-K filed by PolyPid Ltd.
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
- PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
- PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
- PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
- PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
- SEC Form 3 filed by new insider Jacobovitz Yitzchak Shlomo